NOVEL POLYPEPTIDE ORIGINATING FROM HEMOPHILUS PARAGALLINARUM AND PROCESS FOR PRODUCING THE SAME

Abstract: A novel polypeptide from Haemophilus paragallinarum useful for prevention of avian infectious coryza is provided. A novel polypeptide from Haemophilus paragallinarum which induces production of HI antibody and prevents infection and onset of avian infectious coryza, a gene coding for said polypeptide, a recombinant vector for expression of said gene, a host transformed with said vector, a process for preparing said polypeptide wherein said polypeptide is produced by said host, a vaccine for avian infectious coryza comprising as an active ingredient said polypeptide, a monoclonal antibody obtained by using said polypeptide as an immunogen and a diagnostic agent and a therapeutic agent for avian infectious coryza utilizing said peptide and said antibody.

Description: TECHNICAL FIELD The present invention relates to a polypeptide which can prevent avian infectious coryza. More particularly, the present invention relates to a polypeptide from Haemophilus paragallinarum , the causative agent of avian infectious coryza, a gene coding for said polypeptide and an antibody protein which recognizes said polypeptide. The present invention further relates to a process for preparing said polypeptide and the use of said polypeptide for a vaccine, a diagnostic agent and a therapeutic agent. BACKGROUND ART Avian infectious coryza is one of the most important respiratory diseases in poultry, which is an acute respiratory disease caused by infection with Haemophilus paragallinarum (hereinafter also referred to as "HPG") with cardinal symptoms being a running nose, swelling of the face and epiphora. Avian infectious coryza brings about a great economical damage since it leads to decrease in the breeding rate of poultry, retarding of egg laying, decrease in egg production or failure of egg laying. For prevention of avian infectious coryza, an inactivated vaccine has hitherto been used widely which is obtained by culturing Haemophilus paragalinarum , recovering and inactivating the cells with formalin, thimerosal and the like. However, adverse side effects caused by such an inactivated vaccine has been an issue as it has been reported that local necrotic lesions are formed in the inoculated chicken when the vaccine is administered (M. Matsumoto and R. Yamamoto, Avian Dis., 15: 109-117, 1971), and hence, development of a highly safe vaccine is earnestly desired. In recent years, laborsaving in breeding and managing poultry is in progress with a scale-up of breeding poultry. As a part of this, laborsaving in vaccination has also been earnestly desired, and as a result, a mixed vaccine has already been developed and widely used in the field so that a frequency of inoculation can be reduced by mixing several kinds of vaccines together. In order to provide a mixed vaccine showing immunogenicity equivalent to that of each plain vaccine without increase of dosage amount, it is necessary to increase an amount of each antigen contained in a mixed vaccine or to find out and use a more suitable adjuvant. However, in case of gram-negative bacteria such as HPG, a higher amount of antigen is likely to enhance a response to injection such as swelling at the inoculated site. Therefore, in order to reduce such an adverse response, it is preferable to obtain only a protective antigen, i.e. an effective component, from bacterial cells or culture supernatant, or to clone a gene coding for said antigen by the genetic recombination technique, to express said gene in bacteria, yeast, an animal cell, a plant cell, an insect cell and the like, and to purify a product expressed in a large amount, which is then mixed with an appropriate adjuvant together with other vaccines. Another approach for laborsaving of vaccination is the use of virus or bacteria as a vector. That is, genes coding for protective antigens from one or plural pathogens have been incorporated into an attenuated virus or bacteria to prepare a polyvalent live vaccine. For fowls, poxvirus, Marek's disease virus and the like have been investigated as a vector. A vaccine comprising a viral vector has been put into practice wherein genes coding for HN and F proteins of Newcastle disease virus are incorporated into fowl pox virus. It is thus most important to identify a protective antigen of HPG for development of a safe and effective vaccine against avian infectious coryza both as a component vaccine and as a vector vaccine. Among protective antigens of HPG such as hemagglutinin (HA) and outer-membrane protein, HA is considered a most important antigen since immunization of chicken with HPG increases a hemagglutination-inhibition antibody (hereinafter referred to as "HI antibody") and higher protective effect is observed for chickens with high level of HI antibody (K. Otsuki and Y. Iritani, Avian Dis., 18: 297-304, 1974 and K. Kume et al., Jpn. J. Vet. Sci., 46: 843-850, 1984). Serotype of HPG is classified into serotypes A, B and C (Page, Am. J. Vet. Res., 23: 85-95, 1962) or into serotypes 1 and 2 (Sawata et al., Jpn. J. Vet. Sci., 40: 645-652, 1978) based on the agglutination test. It is considered that serotype A by Page corresponds to serotype 1 by Sawata et al. whereas serotype C by Page corresponds to serotype 2 by Sawata et al. (K.Kume, et al., Am. J. Vet. Res., 41: 757-760, 1980 and Sawata et al., Am. J. Vet. Res., 41: 1901-1904, 1980). Kume et al. reported that HPG serotype A (serotype 1) has at least three kinds of HA, i.e. HA-L (heat-labile, trypsin-sensitive), HA-HL (heat-labile, trypsin-resistant) and HA-HS (heast-stable, trypsin-resistant), and that HA-L alone exhibits not only HA activity to usual fresh chicken erythrocytes but also to glutaraldehyde-fixed chicken erythrocytes and is involved in protection against infection with HPG serotype A (K. Kume, Jpn. J. Vet. Sci., 45: 783-792, 1983 and Sawata et al., Jpn. J. Vet. Sci., 46: 21-29, 1984). Iritani et al. reported that HPG serotype A has two kinds of HA, i.e. type 1 HA (heat-labile, protease-sensitive) and type 2 HA (heat-labile, protease-resistant), and that type 1 HA, which is heat-labile and protease-sensitive and consisted of a polypeptide having a molecular weight of about 39 kd as a subunit, is involved in protection against infection (T. Yamaguchi and Y Iritani, Jpn. J. Vet. Sci., 42: 709-711, 1980 and Y. Iritani et al., Am. J. Vet. Res., 41: 2114-2118, 1980). It is considered that HA-L and HA-HL by Kume et al. correspond to type 1 HA and type 2 HA by Iritani et al., respectively. As to HPG serotype C (serotype 2), Sawata et al. reported that an antigen was found which is heat-labile and trypsin-sensitive and exhibits the HA activity to glutaraldehyde-fixed chicken erythrocytes and that this antigen is distinct from HA of HPG serotype A in their antigenicity (Sawata et al., Am. J. Vet. Res., 43: 1311-1314, 1982). However, to date, a protective antigen of HPG has not yet materially identified except for type 1 HA produced by HPG serotype A as reported by Iritani et al. As mentioned hereinabove, the conventional inactivated vaccine obtained by inactivating Haemophilus paragallinarum cells with thimerosal, formalin and the like has provoked problems that the adverse side effects as mentioned above are induced when it is applied to fowls at a large amount since it includes various substances from the cells other than the protective antigen. DISCLOSURE OF INVENTION The inventor has earnestly studied in order to solve the problems, and as a result, has successfully purified, from a culture supernatant of Haemophilus paragallinarum serotype A, a polypeptide having about 130 kd of molecular weight from Haemophilus paragallinarum serotype A, said polypeptide inducing production of HI antibody and protecting against avian infectious coryza by Haemophilus paragallinarum serotype A. Furthermore, the present inventor has prepared a genomic DNA library from HPG serotype A, cloned a gene fragment coding for the above 130 Kd polypeptide expressed said gene fragment in E. coli and has found that the produced polypeptide could prevent avian infectious coryza by Haemophilus paragallinarum serotype A. Said gene fragment coding for the above 130 Kd polypeptide was also used as a probe for cloning a gene fragment hybridizable with said DNA fragment from HPG serotype C to give E. coli which expresses the polypeptide from HPG serotype C. The present invention provides a safer, effective vaccine against avian infectious coryza, pathogenic bacteria of which is Haemophilus paragallinarum , with less adverse side effects and a process for preparing the same. That is, an object of the present invention is to provide a novel polypeptide from Haemophilus paragallinarum as well as a peptide which shares at least a portion of the amino acid sequence. Another object of the present invention is to provide a gene coding for said novel polypeptide from Haemophilus paragallinarum as well as the peptide which shares at least a potion of the amino acid sequence and a recombinant vector for expression of said gene. Still another object of the present invention is to provide a process for preparing said novel polypeptide from Haemophilus paragallinarum and the polypeptide which shares at least a portion of the amino acid sequence from microorganisms or cells transformed with said recombinant vector. Still further object of the present invention is to provide a monoclonal or polyclonal antibody which is prepared by using as an immunogen the thus prepared novel peptide from Haemophilus paragallinarum or the polypeptide which shares at least a portion of the amino acid sequence. Still another object of the present invention is to provide a method for detecting Haemophilus paragallinarum or an antibody thereto by a combination of the above-mentioned peptide, DNA fragment, transformant or antibody. Still further object of the present invention is to provide a therapeutic agent for avian infectious coryza which comprises as an active ingredient the antibody against the novel polypeptide from Haemophilus paragallinarum . BRIEF DESCRIPTION OF DRAWINGS Figure 1 shows the results obtained by challenging chickens with Haemophilus paragallinarum serotype A strain 221 after passive immunization with monoclonal antibodies (clones HpgA 59-40, HpgA 59-180 and HpgA 59-284) wherein the onset of the disease was retarded in the groups previously administered with the monoclonal antibodies having the HI activity (clones HpgA 59-40 and HpgA 59-180). Figure 2 shows the results obtained by challenging chickens with Haemophilus Paragallinarum serotype A strain 221 after passive immunization with monoclonal antibodies (clones HpgA 59-33, HpgA 59-48B and HpgA 59-180) wherein the onset of the disease was retarded in the groups previously administered with the monoclonal antibody having the HI activity (clone HpgA 59-180). Figure 3 shows the results obtained by challenging chickens with Haemophilus paragallinarum serotype A strain 221 after passive immunization with monoclonal antibodies (clones HpgA 59-48A, HpgA 59-145 and HpgA 59-180) wherein the onset of the disease was retarded in the groups previously administered with the monoclonal antibodies having the HI activity (clones HpgA 59-145 and HpgA 59-180). Figure 4 shows the results obtained by challenging chickens with Haemophilus paragallinarum serotype A strain 221 after passive immunization with monoclonal antibodies (clones HpgA 59-188, HpgA 59-236 and HpgA 59-180) wherein the onset of the disease was retarded in the groups previously administered with the monoclonal antibody having the HI activity (clone HpgA 59-180). Figure 5 is a photograph showing the result of SDS-PAGE with CBB staining of HPGp130 polypeptide which is purified by affinity chromatography using the monoclonal antibody having the HI activity (clone HpgA 59-180) as a ligand. Figure 6 is (a) a photograph showing the results of SDS-PAGE with CBB staining of the purified HPGp130 polypeptide and Haemophilus paragallinarum serotype A strain 221 treated with 2-mercaptoethanol; and (b) a photograph showing the results of detection of proteins reactive with guinea pig antiserum against the purified HPGp130 polypeptide after SDS-PAGE of the purified HPGp130 polypeptide and Haemophilus paragallinarum serotype A strain 221 treated with 2-mercaptoethanol and transferring to a thin membrane (PVDF). Figure 7 is a schematic illustration showing the position of HPG1.2k DNA, HPG3.5k DNA, HPG4.1k DNA, HPG6.7k DNA and HPG2.7 k DNA fragments cloned from the genome of Haemophilus paragallinarum serotype A strain 221. Figure 8 is a schematic illustration showing construction of plasmid pSA4.1 by inserting the XhoI-XbaI fragment (HPG4.1k DNA) from the genome of Haemophilus paragallinarum serotype A strain 221 into plasmid pSP72, followed by construction of plasmid pTA4.1 by inserting the XhoI-KpnI fragment from the plasmid pSA4.1 into plasmid pTrcHisC. Figure 9 is a schematic illustration showing construction of plasmid pSA6.7 by inserting the XhoI-PstI fragment (HPG6.7k DNA) from the genome of Haemophilus paragallinarum serotype A strain 221 into plasmid pSP72, followed by construction of plasmid pSA2.7 by inserting the XbaI fragment from the plasmid pSA6.7 into plasmid pSP72. Figure 10 is a photograph showing the results of detection of DNA fragments hybridizable with HPG1.2k DNA as a probe after agarose electrophoresis of DNA fragments obtained by digesting the genome from Haemophilus paragallinarum serotypes A, B and C with restriction enzyme EcoRI and transferring to a thin membrane (Hybond N+). Figure 11 is a schematic illustration showing the position of HPG-C1 DNA, HPG-C2 DNA, HPG-C3 DNA and HPG-C4 DNA fragments cloned from the genome of Haemophilus paragallinarum serotype C strain 53-47. Figure 12 is a photograph showing the result of 0.8 % agarose gel electrophoresis of PCR products obtained by PCR with primers prepared on the basis of the nucleotide sequences coding for the N-terminal and C-terminal amino acid sequences of HPG serotype A HMTp210 polypeptide and the genome of Haemophilus paragallinarum serotype A, B or C as a template. BEST MODE FOR CARRYING OUT THE INVENTION The present invention is explained in more detail hereinbelow. The polypeptide from Haemophilus paragallinarum serotype A of the present invention which induces production of the HI antibody is prepared from a culture supernatant of HPG serotype A or a suspension of ruptured cells by affinity chromatography with the monoclonal antibody having the HI activity as a ligand. The monoclonal antibody having the HI activity (hereinafter also referred to as "HI-MCA") is obtained by preparing the hybridomas producing the monoclonal antibodies which bind to Haemophilus paragallinarum serotype A by the conventional cell fusion procedure and then screening the hybridoma producing the monoclonal antibody having the HI activity with HI test. For use as an immunogen for production of the above antibody, Haemophilus paragallinarum serotype A is obtained by the conventional procedure used for usual culture of Haemophilus paragallinarum . For example, the cells of HPG strain 221 can be recovered by shaking culture in a chicken meat infusion medium supplemented with chicken serum (including chicken meat infusion 300 ml, chicken serum 10 ml, polypeptone 5 g, glucose 1 g, casamino acid 1 g, sodium glutamate 5 g, sodium chloride 5 g, nicotinamide adenine dinucleotide 0.025 g in 1000 ml medium) at 37°C overnight followed by centrifugation. Immunization can be carried out in a usual manner, for example, after inactivating Haemophilus paragallinarum serotype A with thimerosal, formalin and the like, by administering the inactivated cells together with the conventional adjuvant to BALB/c mouse via intraperitoneal, subcutaneous, intradermal or intravenous administration. The immunogen includes HPG cells per se, or alternatively, the cells treated with potassium rhodanide, sonication or hyaluronidase, or a processed antigen obtained by treatment with a surfactant such as sodium N-lauroylsarcosinate, Nonidet P-40 or Triton X-100. The adjuvant includes Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum hydroxide gel, and the like. More specifically, immunization is conducted as follows: Haemophilus paragallinarum serotype A strain 221 cultured in a chicken meat infusion medium supplemented with chicken serum is inactivated with thimerosal and then sonicated. An emulsion obtained by mixing the resultant suspension of ruptured cells with Freund's complete adjuvant is administered subcutaneously to the back of BALB/c mouse, followed by subcutaneous administration of an emulsion prepared from the same amount of the suspension and Freund's incomplete adjuvant at the back every 2 to 4 weeks. A serum antibody level is monitored, and after confirming the elevated level of antibody titer, a suspension of ruptured cells after sonication is further administered intravenously after additional 2 to 4 weeks as a final immunization. As an immunocyte for preparing a monoclonal antibody, splenocytes removed 2 to 4 days after the final administration is preferably used. Mouse myeloma cells include, for example, NSI-Ag4/1 (Eur. J. Immunol., 6: 511, 1976), P3X63-Ag8.U1 (Curr. Topics Microbiol. Immunol., 81:1, 1978), X63-Ag8.653 (J. Immunol., 123: 1548, 1979), and the like. Fusion of splenocytes with mouse myeloma cells may be carried out in accordance with Milstein et al., Method Enzymol., 73, 3-46,1981. That is, fusion can be carried out with approximately 1 to 10 folds higher amount of splenocytes than mouse myeloma cells. A cell fusion promoting agent may be polyethylene glycol having a molecular weight of 1,000-6,000 at a concentration of 30 to 50 % (w/v). More specifically, cell fusion is preferably carried out with about 10 8 splenocytes and about 10 7 P3X63-Ag8.U1 myeloma cells in a culture medium usually used for culture of lymphocytes such as RPMI 1640 medium, containing 45 % polyethylene glycol 4,000, which is previously heated at 37°C. Hybridoma may be obtained by culture in HAT medium for a sufficient period of time so that the non-fused cells cannot survive, usually for several days to several weeks. The thus obtained hybridomas are then used for selection and cloning of strains producing a desired antibody in accordance with the usual limiting dilution procedure, using the culture supernatant of the hybridomas. Screening of strains producing an antibody recognizing Haemophilus paragallinarum serotype A is carried out in accordance with the usual ELISA, RIA, Western blotting, and the like. An antigen used in these methods may be either a suspension of Haemophilus paragallinarum serotype A cells, the cells treated with potassium rhodanide, sonication, hyaluronidase, and the like, or an extraction of said cells with a surfactant. Then, strains producing an antibody having the HI activity are screened in accordance with the usual HI test, using a culture supernatant of the above hybridomas or ascites from mouse administered with said hybridomas. HA antigen includes a suspension of Haemophilus paragallinarum cells or the cells treated with potassium rhodanide, sonication, hyaluronidase, and the like. Erythrocytes used for HI test may be either 0.5 % fresh chicken erythrocytes, glutaraldehyde-fixed 1 % chicken erythrocytes or formalin-fixed chicken erythrocytes, with glutaraldehyde-fixed chicken erythrocytes being preferable. More specifically, a supernatant obtained after centrifugation of ascites treated with 5 folds amount of a 25 % kaolin solution is added to precipitates of glutaraldehyde-fixed chicken erythrocytes, which is then shaken at 37°C for 60 minutes for sensitization. To a twofold serial dilution of this supernatant is added the same amount of a suspension of strain 221 cells including 4 hemagglutinin units and the mixture is left to stand for 15 minutes. Thereto is added a suspension of glutaraldehyde-fixed 1 % chicken erythrocytes, the mixture is left to stand at room temperature for 60 minutes, and observed at the bottom of microtiter plate. An HI antibody titer is defined as a maximum dilution which can block hemagglutination. Recovery of monoclonal antibodies having the HI activity from the thus obtained hybridomas is carried out by culturing said hybridomas in a large amount and harvesting said antibodies from the culture supernatant, or by administering said hybridomas to mice compatible with said hybridomas so that said hybridomas are proliferated and harvesting said antibodies from the ascites thereof. Purification of the monoclonal antibody may be done by the conventional procedures used in the protein chemistry such as, for example, a salting out, ultrafiltration, an isoelectric precipitation, an electrophoresis, an ion exchange chromatography, a gel filtration chromatography, an affinity chromatography, and the like. More specifically, purification of the monoclonal antibody from ascites may be done using Protein A-Sepharose CL-4B (manufactured by Pharmacia) and MAPS-II Mouse Monoclonal Antibody Purification Kit (manufactured by Bio Rad) in accordance with protocol of the manufacturer. An affinity column with the antibody having the HI activity as a ligand for purification of the polypeptide from Haemophilus paragallinarum serotype A which induces production of the HI antibody may be prepared by a usual procedure, for example, by binding the above purified antibody to HiTrap NHS-Activated Column (manufactured by Pharmacia) in accordance with protocol of the manufacturer. Using the thus prepared affinity column, the polypeptide from Haemophilus paragallinarum serotype A which induces production of the HI antibody may be obtained from a culture supernatant of HPG serotype A cells or from a suspension of ruptured cells. Specifically, a polypeptide (hereinafter referred to as "HPGp130") with a molecular weight of about 130 Kd having a high capacity to produce the HI antibody and the activity to prevent avian infectious coryza was obtained from a culture supernatant of HPG strain 221 cultured in the chicken meat infusion medium supplemented with chicken serum at 37°C for two days. An amino acid sequence of the thus obtained polypeptide may be determined by the usual procedures such as Edman degradation (P. Edman, Acta Chem. Scand., 4: 283, 1950). The amino acid sequence at the N-terminal of said polypeptide is shown in SEQ ID NO: 2. Cloning of a gene or a gene fragment coding for the polypeptide from Haemophilus paragallinarum serotype A may be done by the usual procedures as described by Sambrook et al. (Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, New York, 1989). That is, Haemophilus paragallinarum serotype A strain 221 cells are cultured and recovered by the above procedures, a genomic DNA is extracted and purified with Sepagene kit (manufactured by Sanko Junyaku K.K.) in accordance with protocol attached thereto. The genomic DNA is then cleaved with a commercially available restriction enzyme (preferably EcoRI), the obtained DNA fragments are inserted into a commercially available cloning vector (e.g. λgt11) to prepare a DNA library, among which such clones expressing the antigen that responds to the desired antibody having the HI activity are screened. The antibody having the HI activity includes the culture supernatant of the hybridomas or the ascites of mice obtained as mentioned above. Antisera is preferably used which is obtained by immunization with the polypeptide from Haemophilus paragallinarum serotype A isolated by affinity chromatography with the monoclonal antibody having the HI activity as a ligand. A nucleotide sequence of the exogenous DNA fragment in the thus obtained recombinant λgt11 phage DNA may be determined with a DNA sequencer (for example, Applied Biosystems 377). Novelty of the obtained exogenous DNA fragment may be confirmed by homology search between the whole nucleotide sequence and the existing data base (for example, GeneBank, EMBL, and the like). As shown in Example 3, for example, ten positive λgt11 phages were obtained from the DNA library and each DNA of these phages included an exogenous DNA fragment of about 1.2 kb (hereinafter also referred to as "HPG1.2k DNA fragment") as demonstrated in an agarose electrophoresis. The nucleotide sequence of said exogenous DNA corresponds to the nucleotide sequence of from nucleotides No. 1988 to No. 3157 of SEQ ID NO: 1. Since an initiation codon and a termination codon are not found in the HPG1.2k DNA, this DNA fragment is considered to encode a portion of the polypeptide from Haemophilus paragallinarum serotype A. A gene coding for a full length of said polypeptide may be obtained by using the HPG1.2k DNA as a probe to give a longer DNA fragment, determining a nucleotide sequence of this DNA fragment and finding out an initiation codon and a termination codon. More specifically, the genomic DNA of Haemophilus paragallinarum serotype A strain 221 is cleaved with a restriction enzyme whose cleavage site is not present in the 1.2 kb DNA (for example, HindIII) and the resulting DNA fragments are separated with an agarose electrophoresis. Using DIG-DNA Labeling Kit (manufactured by Boehringer Mannheim), Southern hybridization is carried out using digoxigenin (DIG)-labeled 1.2 kb DNA fragment as a probe for detecting desired DNA fragments. As a result, there was obtained a HindIII-digested DNA fragment of about 3.5 kb which hybridized with the 1.2 kb DNA fragment (hereinafter also referred to as "HPG3.5k DNA fragment"). A nucleotide sequence of the HPG3.5k DNA fragment corresponds to the nucleotide sequence of from nucleotides No. 1 to No. 3450 of SEQ ID NO: 1. An identical sequence to the amino acid sequence at the N-terminal of the above HPGp130 polypeptide was found at the amino acid sequence of from amino acid residues No. 1 to No. 13 (corresponding to nucleotide sequence of from No. 453 to No. 491) in SEQ ID NO: 1. Since only an initiation codon was found in the HPG3.5k DNA but a termination codon was not, the 1.2 kb DNA fragment and the 3.5 kb DNA fragment labeled with DIG were used as a probe to give a XhoI-XbaI digested DNA fragment of about 4.1 kb (hereinafter also referred to as "HPG4.1k DNA fragment"). A nucleotide sequence of the HPG4.1k DNA fragment corresponds to the nucleotide sequence of from nucleotides No. 2212 to No. 6275 of SEQ ID NO: 1. Since a termination codon was not found in the HPG4.1k DNA fragment, a XhoI-PstI digested DNA fragment of about 6.7 kb (hereinafter also referred to as "HPG6.7k DNA fragment"; this fragment encompasses the above HPG4.1k DNA fragment) was obtained using the 1.2 kb DNA and the 3.5 kb DNA labeled with DIG. A nucleotide sequence of the HPG6.7k DNA fragment corresponds to the nucleotide sequence of from nucleotides No. 2212 to No. 8930 of SEQ ID NO: 1. There existed a termination codon in the HPG6.7k DNA fragment. It was found that the nucleotide sequence of SEQ ID NO: 1, consisting of a total of 8930 nucleotides, included an open reading frame starting from nucleotide No. 243 which can code for 2042 amino acid residues. A polypeptide comprising the 2042 amino acid residues is hereinafter also referred to as "serotype A HMTp210". Homology search with the existing data base (GeneBank and EMBL) revealed no homology with any known nucleotide and amino acid sequences, indicating that the serotype A HMTp210 polypeptide is a novel substance. The presence of another possible open reading frame in the nucleotide sequence of SEQ ID NO: 1 was also suggested which starts from nucleotide No. 8375 and can code for 185 amino acid residues. No termination codon was found in this sequence. Homology search with the existing data base (GeneBank and EMBL) revealed no homology with any known nucleotide and amino acid sequences, indicating that the polypeptide coded by this open reading frame is also a novel substance. The DNA fragments from Haemophilus paragallinarum serotype A can also be used as a probe for obtaining DNA fragments from different serotype of Haemophilus paragallinarum such as serotype B or serotype C as well as polypeptides coded by said DNA fragments. More specifically, a genomic DNA is extracted and purified from HPG serotype C strain 53-47 and cleaved with a suitable restriction enzyme (preferably HindIII), the obtained DNA fragments are inserted into a commercially available cloning vector (e.g. λDASHII) to prepare a DNA library, among which clones are screened by using the serotype A HPG3.5k DNA fragment labeled with DIG as a probe. As shown in Example 5, ten positive λDASHII phages were obtained from the DNA library and each DNA of these phages included an exogenous DNA fragment of about 13.5 kb (hereinafter also referred to as "HPG-C1 DNA") as demonstrated in an agarose gel electrophoresis. Since the HPG-C1 DNA fragment of about 13.5 kb is too large to be subcloned into a plasmid vector, it was cleaved with a suitable restriction enzyme (preferably XbaI) and the resulting DNA fragments were inserted into a commercially available cloning vector (for example, pUC119). As a result, DNA fragments of about 5.6 kb (hereinafter also referred to as "HPG-C2 DNA"), about 0.9 kb (hereinafter also referred to as "HPG-C3 DNA") and about 6.9 kb (hereinafter also referred to as "HPG-C4 DNA") were obtained. A nucleotide sequence of a portion of HPG-C2 DNA fragment and HPG-C4 DNA fragment was determined to reveal the presence of an initiation codon and a termination codon in these DNA fragments, respectively. It was found that the nucleotide sequence of SEQ ID NO: 5, consisting of a total of 7486 nucleotides, included an open reading frame starting from nucleotide No. 848 which can code for 2039 amino acid residues. A polypeptide comprising the 2039 amino acid residues is hereinafter also referred to as "serotype C HMTp210". Homology search with the existing data base (GeneBank and EMBL) revealed no homology with any known nucleotide and amino acid sequences, indicating that the serotype C HMTp210 polypeptide is a novel substance. Homology search between the nucleotide sequences coding for the serotype C HMTp210 polypeptide and the serotype A HMTp210 polypeptide revealed about 80 % homology. It was further revealed that the region of about 3.4 kb at the 5' site and the region of about 1.2 kb at the 3' site exhibited extremely high homology whereas the region of about 1.5 kb between these 5' and 3' regions showed low homology. The same was also applicable to the corresponding polypeptides encoded by these genes. Based on the nucleotide sequence coding for the serotype A HMTp210 polypeptide, there can also be obtained, by PCR, DNA fragments from different serotype of Haemophilus paragallinarum such as serotype B or serotype C as well as polypeptides coded by said DNA fragments. More specifically, based on the nucleotide sequence coding for the serotype A HMTp210 polypeptide, there were prepared a synthetic DNA having the nucleotide sequence of SEQ ID NO: 3 as an upstream PCR primer and a synthetic DNA having the nucleotide sequence of SEQ ID NO: 4 as a downstream PCR primer. These primers were designed such that BamHI recognition sequences were added at the 5' sites, respectively, and a full length of translation region of the serotype A HMTp210 polypeptide can be amplified. Using these primers, PCR was carried out using as a template the genomic DNAs from a total of nine strains, i.e. Haemophilus paragallinarum serotype A strains 221, 083, W, Germany and Georgia, HPG serotype B strains Spross and 0222, and HPG serotype C strains Modesto and 53-47. Analysis of the obtained PCR products on 0.8 % agarose gel electrophoresis confirmed the amplified fragment of about 6.1 kb in any of these strains. The thus obtained DNA fragment or a portion thereof may be incorporated into a suitable expression vector, the resulting expression vector is used for transformation of a microorganism or an animal cell, and the transformant is cultured to produce the polypeptide of the present invention from Haemophilus paragallinarum or a peptide which shares at least a portion of the amino acid sequence of said polypeptide. The peptide which shares a portion of the amino acid sequence can also be produced with a peptide synthesizer. A suitable signal sequence for secretion in a microorganism or an animal cell can also be linked upstream the DNA coding for the polypeptide of the present invention so that said polypeptide can be secreted into a culture medium. The thus modified DNA for secretion is advantageous in that said polypeptide secreted into a culture medium can easily be purified. A signal sequence includes pelB signal (S. P. Lei et al., J. Bacteriology, 169: 4379-4383, 1987) for E. coli , signal from α factor (A. J. Brake, Yeast Genetic Engineering, p269, Butterworth, 1989) for yeast, signal SG-1 from immunoglobulin (H. Maeda et al., Hum. Antibod. Hybridomas, 2: 124-134, 1991), C25 signal (PCT International Publication No. WO94/20632) for an animal cell. An expression vector includes a plasmid, a viral vector and the like. Any promoter may be included in the expression vector such as lac, tac, pho5, adh, SV40 early, SV40 late, β actin and the like, in consideration of a microorganism or an animal cell used as a host, insofar as the polypeptide having the activity to prevent avian infectious coryza is ultimately obtained. The polypeptide of the present invention can also be expressed as a fusion protein with another protein or peptide such as β-galactosidase, glutathione-S-transferase, maltose binding protein, Protein A, histidine hexamer, and the like. A marker gene includes, in case of an expression vector for a microorganism cell, ampicillin resistant gene, tetracycline resistant gene for E. coli as a host, β-isopropyl malate dehydrogenase (Leu2) gene for yeast as a host, and in case of an expression vector for an animal cell, aminoglycoside 3' phosphotransferase (neo) gene, dihydrofolate reductase (dhfr) gene, glutamine synthetase (GS) gene, and the like. An additive for selection includes G418, neomycin, methotrexate, and the like. Transformation of a host cell may be carried out by the known methods including, for example, a calcium chloride method, a calcium phosphate coprecipitation method, a DEAE dextran method, a lipofectin method, a protoplast polyethylene fusion method, an electroporation, and the like, which can suitably be selected depending on a host used. The novel polypeptide of the present invention from Haemophilus paragallinarum or a peptide which shares at least a portion of the amino acid sequence of said polypeptide may be prepared as described hereinbelow. For example, the HPG3.5k DNA fragment from HGP serotype A is incorporated into an expression vector pTrcHisC (manufactured by Invitrogen), said expression vector is introduced into E. coli strain JM109 for transformation. Among the resulting transformed cells, those transformants which produce the target novel polypeptide are screened by a dot blotting with an index of reactivity with the antibody against said polypeptide. Chicken immunized with a supernatant obtained after centrifugation of a suspension of the ruptured cells have an elevated protection against challenge with HPG serotype A strain 221. The novel polypeptide may be purified from an extract of cells or a culture supernatant from a large scale culture of the transformant producing said polypeptide by utilizing the above-mentioned methods used in the field of protein chemistry. The thus obtained novel polypeptide from Haemophilus paragallinarum has the activity to prevent avian infectious coryza. Said polypeptide from Haemophilus paragallinarum , monoclonal and polyclonal antibodies against said polypeptide and the expression vector as mentioned above may be used as a vaccine or a therapeutic agent for avian infectious coryza either alone or in combination with a suitable carrier, diluent or stabilizing agent in a conventional manner such as injections or oral drugs. The above novel polypeptide from Haemophilus paragallinarum or a polypeptide which shares at least a portion of the amino acid sequence of said polypeptide may be used as an immunogen for preparing a polyclonal and monoclonal antibodies in accordance with the procedures described hereinabove. Said polypeptide as well as the antibody having the capacity to bind thereto may also be utilized in an antigen or antibody detection system such as Western blot, ELISA, and the like, and may also be a material for constructing a diagnostic agent. In addition, affinity chromatography with a suitable carrier to which the above antibody is bound may be used for purification of the above polypeptide. In accordance with the present invention, there are provided the novel polypeptide from Haemophilus paragallinarum and the gene fragment coding for said polypeptide for prevention of avian infectious coryza and the antibody having the HI activity which can be used as a therapeutic agent. The polypeptide from Haemophilus paragallinarum , which the present inventor has found, has a molecular weight of about 130 Kd, has the activity to induce production of the HI antibody, and is the novel, important polypeptide for prevention of avian infectious coryza. Technical problems associated with the obtention of said polypeptide, such as isolation of the gene coding for said polypeptide, construction of the expression vector, preparation of the expression cell, and purification of said polypeptide, are solved by the present invention, which allows for provision of a more effective vaccine than the prior art vaccines. Furthermore, these are useful as a material for providing a rapid, simple diagnostic agent for avian infectious coryza. The present invention is illustrated in more detail by means of the following Examples but should not be construed to be limited thereto. Example 1 : Preparation and features of monoclonal antibody (1) Preparation of monoclonal antibody Haemophilus paragallinarum serotype A strain 221 cells were inoculated to 100 ml of chicken meat infusion medium supplemented with chicken serum and shake-cultured at 37°C overnight, followed by centrifugation (8,000 rpm, 20 minutes) to recover cells. The obtained cells were washed with PBS while centrifugation and then suspended in PBS containing 0.01 % thimerosal at about 5 x 10 10 cells/ml. The suspension was sonicated with Branson Sonifier 350 at 20 kHz, 4°C for 10 minutes (alternative repeat of sonication for 0.5 second and cooling for 0.5 second). The thus obtained suspension of the ruptured cells by sonication was mixed with the same amount of Freund's complete adjuvant and the mixture was well blended till a water-in-oil (w/o) was achieved. Each 0.1 ml of this emulsion was subcutaneously administered to BALB/c mouse at two sites of the back. Four weeks later, each 0.1 ml of an emulsion prepared similarly with Freund's incomplete adjuvant was subcutaneously administered at two sites of the back. After additional 18 days, 0.1 ml of the suspension of the ruptured cells by sonication was intravenously administered. Three days after the final administration, splenocytes were removed. Said splenocytes (1 x 10 8 cells) were mixed with mouse myeloma cells P3X63-Ag8.U1 (1 x 10 7 cells) by padding, thereto was added RPMI1640 medium containing 45 % polyethylene glycol previously warmed at 37°C to conduct cell fusion. The cells after fusion reaction were suspended in HAT medium (RPMI1640 medium containing 5 % fetal calf serum supplemented with 1 x 10 -4 M hypoxanthine, 4 x 10 -7 M aminopterin and 1.6 x 10 -5 M thymidine), and after plated on 96-well microtiter plate for cell culture (manufactured by Coning), cultured under the condition of 37°C and 5 % CO 2 . For the wells where hybridomas propagated, the presence of the monoclonal antibody recognizing Haemophilus paragallinarum in the culture supernatant was determined with ELISA as described hereinbelow. A suspension of ruptured cells by sonication of Haemophilus paragallinarum serotype A strain 221 prepared as mentioned above was diluted 300 folds with PBS and each 100 µl of the suspension was plated on well of microtiter plate for ELISA (Immulon II manufactured by Dynatech). The microtiter plate was left to stand at 4°C overnight and masked with PBS containing 5 % skim milk at 200 µl per well at room temperature for 2 hours. The microtiter plate was washed with PBS containing 0.05 % Tween 20 (PBS-T) and thereto was added 100 µl of the culture supernatant of hybridomas diluted 10 folds with PBS-T containing 5 % skim milk for reaction at room temperature for 2 hours. After washing with PBS-T, each 100 µl of peroxidase-labeled antimouse IgG (manufactured by Bio-Rad) diluted 10,000 folds with PBS-T containing 5 % skim milk was added for reaction at room temperature for 2 hours. Then, after washing with PBS-T, each 100 µl of 0.05 M citrate-0.1 M disodium hydrogenphosphate buffer (pH 5.0) containing 6 mg per 11 ml of ortho-phenylenediamine dihydrochloride (OPD; manufactured by Katayama Kagaku K.K.) and 4.75 µl of hydrogen peroxide (containing H 2 O 2 at 31 %; manufactured by Mitsubishi Gasu Kagaku K.K.) was added for reaction at room temperature for 30 minutes. Each 50 µl of 3 M sulfuric acid was added to quench the reaction and absorbance (490 nm) of each well was measured with Autoreader for ELISA. Hybridomas of the wells where the antibody against Haemophilus paragallinarum serotype A was secreted in the culture supernatant were cloned by a limiting dilution method so that they become monoclonal. Thus, nine clones producing the monoclonal antibody against Haemophilus paragallinarum serotype A were obtained. (2) HI activity of monoclonal antibodies These hybridomas were cultured in a large amount and intraperitoneally administered to BALB/c mice, pretreated with an immunosuppressive agent, pristane (2,6,10,14-tetramethylpentadecane; manufactured by Aldrich), where the hybridomas propagated. Ten to twenty days later, the mice were sacrificed and the produced ascites were removed therefrom and HI activity of the ascites was determined. A suspension of Haemophilus paragallinarum serotype A strain 221 cells inactivated with thimerosal was used as an HA antigen for HI test and prepared based on HA titer. First, using a V-shaped microtiter plate (Sanko Junyaku K.K.), a suspension of a glutaraldehyde-fixed 1 % chicken erythrocytes (0.05 ml) was added to a 2 folds serial dilution of HA antigen (0.05 ml), and after standing at room temperature for 60 minutes, the bottom of the plate was observed. A maximum dilution which agglutinates erythrocytes was defined as HA titer and, regarding a concentration of HA antigen at this dilution as 1 unit, a stock solution of HA antigen was prepared so that it contains 4 units. Then, to 0.2 ml of mouse ascites was added 5 folds amount of 25 % kaolin solution and the mixture was shaken at 37°C for 30 minutes for sensitization, followed by centrifugation to give a supernatant. This supernatant of centrifugation after kaolin treatment was added to precipitates obtained by centrifugation of glutaraldehyde-fixed 10 % chicken erythrocytes (2 ml) and the mixture was shaken for sensitization at 37°C for 60 minutes. After sensitization, a supernatant was obtained by centrifugation and used as 5 folds diluted mouse ascites for determination of HI antibody. Using a V-shaped microtiter plate, to 0.025 ml of a 2 folds serial dilution of this supernatant was added the same amount of the suspension of strain 221 cells inactivated with thimerosal containing 4 hemagglutination units and, after mixing, the mixture was left to stand for 15 minutes. After sufficient sensitization, 0.05 ml of a suspension of glutaraldehyde-fixed 1 % chicken erythrocytes was added. After the mixture was left to stand at room temperature for 60 minutes, the bottom of the microtiter plate was observed. A maximum dilution which inhibits hemagglutination was defined as an HI antibody titer. Among nine clones, the monoclonal antibodies from three clones (HpgA 59-40, HpgA 59-145 and HpgA 59-180) exhibited a high HI activity (Table 1). The clone HpgA 59-180 has been deposited by the applicant as FERM BP-6084 at National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken) on September 5, 1996. Monoclonal antibody HI antibody titer HpgA 59-33 <50 HpgA 59-40 25,600 HpgA 59-48A <50 HpgA 59-48B <50 HpgA 59-145 1,600 HpgA 59-180 12,800 HpgA 59-188 <50 HpgA 59-236 <50 HpgA 59-284 <50 (3) Protective activity of monoclonal antibodies A mouse ascites (0.3 ml) containing these antibodies was intraperitoneally administered to SPF white leghorn chickens of 4 to 6 weeks old, each group comprising 8 to 10 chickens, and on the next day, about 10 8 cells of Haemophilus paragallinarum serotype A strain 221 were applied dropwise to the nasal cavity of the chickens for challenge. A control group which was given no mouse ascites was also used and was challenged in the same manner. Each group was observed for the presence of the coryza symptoms (i.e. a running nose, swelling of the face and epiphora) for 10 days. All the groups which previously received the monoclonal antibodies having the HI activity (hereinafter also referred to as "HI-MCA") were likely to retard the onset as compared to the control group. On the contrary, all the groups administered with the monoclonal antibodies of the other clones showed no significant difference (Figs. 1 to 4). Example 2 : Purification and property of antigen recognized by HI-MCA (1) Purification of HI-MCA HI-MCA (HpgA 59-180) was purified from mouse ascites using Protein A-Sepharose CL-4B (manufactured by Pharmacia) and MAPS-II Mouse Monoclonal Antibody Purification Kit (manufactured by Bio-Rad) in accordance with protocol attached thereto. First of all, to 4 ml of mouse ascites was added the same amount of a binding buffer included in the Antibody Purification Kit. After the mixture was filtered with Sterivex filter of 0.45 micron (manufactured by Millipore), it was applied to Protein A-Sepharose CL-4B column (gel bed volume 5 ml) and was thoroughly washed with the binding buffer till less than 0.05 of the absorbance at 280 nm was obtained. Then, the antibodies bound to the column were eluted with an elution buffer included in the kit. The eluted antibodies were dialyzed against 0.2 M sodium hydrogen carbonate (pH 8.3) containing 0.5 M sodium chloride to give 40 mg of purified HI-MCA (HpgA 59-180). Similarly, HI-MCA (HpgA 59-40) was also purified to give 12 mg. (2) Binding of HI-MCA to carrier Then, the purified HI-MCA (HpgA 59-180) as a ligand was bound to HiTrap NHS-activated column (manufactured by Pharmacia) in accordance with protocol attached thereto. First of all, HiTrap NHS-activated column (gel bed volume 1 ml) was washed with 1 mM hydrochloric acid and then circulated with 0.2 M sodium hydrogen carbonate solution (10 ml) containing 0.5 M sodium chloride and 10 mg of the above purified HI-MCA (HpgA 59-180) at room temperature for 30 minutes so that HI-MCA was bound to the column. The obtained HI-MCA-bound HiTrap column was washed each three times alternatively with 0.5 M ethanolamine (pH 8.3) containing 0.5 M sodium chloride, and 0.1 M sodium acetate buffer (pH 4.0) containing 0.5 M sodium chloride and equilibrated with PBS for purification of an antigen recognized by HI-MCA. (3) Purification of antigen recognized by HI-MCA An antigen was purified from a culture of Haemophilus paragallinarum serotype A strain 221 by an affinity chromatography using HI-MCA as a ligand. An antigen was detected by ELISA method as described hereinbelow. The above purified HI-MCA (HpgA 59-40) was diluted with 0.05 M sodium carbonate buffer (pH 9.0) to a concentration of 1.6 µg/ml and was placed in a well of microtiter plate for ELISA. The plate was left to stand at 4°C overnight and masked with PBS containing 5 % skim milk at room temperature for 2 hours. After washing with PBS-T, an eluate from the column diluted 10 folds with PBS-T containing 5 % skim milk was reacted at room temperature for 2 hours. After washing with PBS-T, peroxidase-labeled HI-MCA (HpgA 59-180) diluted 10,000 folds with PBS-T containing 5 % skim milk was reacted at room temperature for 2 hours. Then, after washing with PBS-T, a substrate solution containing OPD and hydrogen peroxide was added for reaction at room temperature for 30 minutes. Peroxidase-labeled HI-MCA (HpgA 59-180) was prepared by binding horseradish peroxidase (manufactured by Toyobo K.K.) to the above purified HI-MCA (HpgA 59-180) as described by Yoshitake et al. (J. Biochem., 92: 1413-1424, 1982). Haemophilus paragallinarum serotype A strain 221 cells were inoculated to 100 ml of chicken meat infusion culture supplemented with chicken serum and shake-cultured at 37°C for 2 days. To a culture supernatant obtained after removal of cells by centrifugation at 8,000 rpm for 20 minutes was immediately added a serine protease inhibitor, phenylmethylsulfonyl fluoride, at 1 mM, and the mixture was filtered with 0.45 micron Sterivex filter. The HI-MCA-bound HiTrap column preequilibrated with PBS was added with 60 ml of the above filtrate and washed with PBS. When the absorbance at 280 nm became less than 0.05, an antigen bound to HI-MCA was eluted with 3M sodium thiocyanate. Antigens recognized by HI-MCA were not found in unbound fractions but in most part were recovered in fractions eluted with 3 M sodium thiocyanate. This eluate was dialyzed against 50 mM Tris-HCl buffer (pH 8.0) containing 50 mM sodium chloride. (4) Amino acid sequence analysis of N-terminal of antigen recognized by HI-MCA After treatment with 2-mercaptoethanol, the eluate from the affinity column was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with 5 to 20 % polyacrylamide gel in accordance with Laemmli, Nature, 227: 680-685, 1970, which was stained with 0.25 % Coomassie Brilliant Blue R250 (CBB) dissolved in 50 % methanol - 10 % acetic acid to reveal a band of a molecular weight about 130 Kd (Fig. 5). This polypeptide was referred to as HPGp130 and an amino acid sequence of the N-terminal was determined as described hereinbelow. First, the purified HPGp130 polypeptide was treated with 2-mercaptoethanol and then subjected to SDS-PAGE using 5 % polyacrylamide gel. After electrophoresis, the gel was washed with a transfer buffer (10 mM N-cyclohexyl-3-aminopropanesulfonic acid, 10 % methanol, pH 11) and overlaid to polyvinylidene difluoride (PVDF) membrane (manufactured by Millipore), which was previously immersed successively in 100 % methanol and a transfer buffer, followed by transfer with TRANS-BLOT CELL (manufactured by Bio Rad) at 20 V overnight. The PVDF membrane after transfer was washed with water and stained with 0.1 % Amido Black dissolved in 45 % methanol - 10 % acetic acid for 30 seconds, followed by decolorization with distilled water. The stained band of a molecular weight 130 Kd was cut out and analyzed with Protein Sequencer (Applied Biosystems 477A). Thirteen amino acid residues at the N-terminal were analyzed, and as a result, the amino acid sequence was found to be Lys-Trp-Leu-Glu-Val-Tyr-Ser-Ser-SerVal-Lys-Leu-Ser as shown in SEQ ID NO: 2. (5) Induction of HI antibody production by HPGp130 Whether HPGp130 polypeptide could induce production of HI antibody was investigated. An emulsion (1 ml; about 20 µg of HPGp130 polypeptide per animal) prepared by mixing the HPGp130 polypeptide solution (about 40 µg/ml) with the same amount of Freund's complete adjuvant was subcutaneously injected to guinea pig at two sites of the back for immunization. About three weeks later, 1 ml of an emulsion prepared similarly with Freund's incomplete adjuvant was injected subcutaneously at two sites of the back. Additional two weeks later, the emulsion prepared with Freund's incomplete adjuvant was boosted subcutaneously at two sites of the back and four weeks thereafter the test animals were bled. HI antibody titer of the obtained antisera was determined as described above to reveal a high HI antibody titer (5,120 folds). Thus, it was found that the HPGp130 polypeptide induced production of HI antibody deeply involved in protection against avian infectious coryza. (6) Peptide recognized by anti-HPGp130 polypeptide guinea pig sera A polypeptide recognized by anti-HPGp130 polypeptide guinea pig serum was analyzed by Western blot. First, the purified HPGp130 polypeptide and HPG serotype A strain 221 cells cultured in chicken meat infusion medium supplemented with chicken serum were treated with 2-mercaptoethanol and subjected to SDS-PAGE. After completion of electrophoresis, the gel was immersed in a transfer buffer (25 mM Tris, 192 mM glycine, 20 % ethanol, pH 8.3) for 5 minutes and overlaid to PVDF membrane, which was previously immersed in 100 % methanol and the transfer buffer in this order, and a transfer was carried out using TRANS-BLOT SD CELL (manufactured by Bio Rad) at 7 V for 1 hour. The membrane was masked with PBS containing 5 % skim milk at 4°C overnight, washed with PBS-T and then reacted with anti-HPGp130 polypeptide guinea pig serum diluted 1,000 folds with PBS-T containing 5 % skim milk at room temperature for 2 hours. After washing with PBS-T, peroxidase-labeled anti-guinea pig IgG (manufactured by Zymed) diluted 2,000 folds with PBS-T containing 5 % skim milk was reacted at room temperature for 2 hours. After washing with PBS-T, the membrane was immersed in 10 ml of 0.1 M Tris-HCl buffer (pH 7.5) containing 5 mg of 3,3'-diaminobenzidine tetrahydrochloride (DAB; manufactured by Dojin Kagaku K.K.) and 3 µl of hydrogen peroxide for reaction. As a result, anti-HPGp130 polypeptide guinea pig serum recognized the HPGp130 polypeptide and a band of a molecular weight about 160 Kd, possibly a precursor of the polypeptide (Fig. 6). (7) Immunogenicity of HPGp130 polypeptide In accordance with the procedures as described hereinabove, ten SPF white leghorn chickens of 5 weeks old were immunized by subcutaneously administering at the leg 0.5 ml of an emulsion (containing about 10 µg of HPGp130 polypeptide) prepared by mixing an HPGp130 polypeptide solution (about 40 µg/ml) and the same amount of Freund's complete adjuvant. Three weeks later, the chickens were subcutaneously administered at the leg with 0.5 ml of an emulsion prepared similarly with Freund's incomplete adjuvant. Two weeks later, the chickens were boosted subcutaneously at the leg with an emulsion prepared similarly with Freund's incomplete adjuvant. Seven weeks after the first immunization, the chickens were challenged with Haemophilus paragallinarum serotype A strain 221. As a control, one group was immunized twice with 0.5 ml of 0.25 % formalin-inactivated HPG serotype A strain 221 (cell number prior to inactivation: 4 x 10 8 cells/ml) supplemented with aluminum hydroxide gel (in terms of aluminum: 0.5 mg/ml) at the interval of three weeks and another group was not immunized and both control groups were challenged similarly. The results are shown in Table 2. Both groups immunized either with HPGp130 polypeptide or formalin-inactivated cells showed protection against the onset of the disease in all the chickens. For the non-immunization group, however, the symptoms were shown in all the chickens. Immunization group Tested chicken Protected chicken Protection rate (%) Purified HPGp130 10 10 100 Formalin-inactivated strain 221 10 10 100 Non immunization control 8 0 0 Example 3 : Cloning of gene coding for polypeptide (serotype A HMTp210) from Haemophilus paragallinarum serotype A strain 221 (1) Screening from genomic library Haemophilus paragallinarum serotype A strain 221 cells were inoculated to 5 ml of chicken meat infusion medium supplemented with chicken serum and shake-cultured at 37°C overnight and the cells were recovered by centrifugation. After washing the obtained cells with PBS by centrifugation, DNA was extracted and purified from the cells with Sepagene kit (manufactured by Sanko Junyaku K.K.) in accordance with protocol attached thereto. The DNA was dissolved in 50 µl of TE buffer (10 mM Tris-HCl buffer containing 1 mM EDTA, pH 8.0) and the obtained solution was used as a genomic DNA solution. Then, using cDNA Rapid Cloning Module-λgt11 (manufactured by Amersham), 0.2 µg of the genomic DNA digested with restriction enzyme EcoRI was ligated to 0.5 µg of λgt11 arm digested with restriction enzyme EcoRI in accordance with protocol attached thereto. Using λ-DNA In Vitro Packaging Module (manufactured by Amersham), the ligated product was inserted into λ phage in accordance with protocol attached thereto. The obtained solutions of recombinant phage were used as a genomic library. The above solutions of genomic library were added to a suspension of E.coli strain Y1090 (manufactured by Amersham) about 10 8 cells in an aqueous solution of 10 mM magnesium sulfate for absorption at 37°C for 15 minutes. Thereto was added LB soft agar medium (containing tryptone 10 g, yeast extract 5 g, sodium chloride 10 g, ampicillin 50 mg, maltose 4 g and agar 8 g in 1000 ml, pH 7) for overlay warmed at 45°C. The mixture was overlaid to LB agar medium (containing tryptone 10 g, yeast extract 5 g, sodium chloride 10 g, ampicillin 50 mg and agar 15 g in 1000 ml, pH 7) and incubated at 42°C for 3 hours. A nitrocellulose membrane immersed in an aqueous solution of 10 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was air-dried, overlaid to the above plate and incubated at 37°C overnight. The nitrocellulose membrane was then peeled off from the plate, washed with PBS-T and masked with PBS containing 5 % skim milk at room temperature for 2 hours. Thereafter, the procedures as described in Example 2 (6) were repeated so that anti-HPGp130 polypeptide guinea pig serum, peroxidase-labeled anti-guinea pig IgG and a substrate were successively reacted. A series of these procedures gave plaques which express an antigen specifically reactive with anti-HPGp130 guinea pig serum from Haemophilus paragallinarum serotype A strain 221. About 5,000 plaques were immunologically screened as described above to give 43 positive plaques. These positive plaques were recovered in an SM buffer (50 mM Tris-HCl buffer containing 0.1 M sodium chloride, 10 mM magnesium sulfate and 0.01 % gelatin, pH 7.5) and, after adding several drops of chloroform, stored at 4°C. Ten among the recovered positive plaques were further subjected to second and third screening as in the primary screening. The recombinant λgt11 phages found positive in the immunological screening were added to a suspension of E. coli strain Y1090 about 10 8 cells in an aqueous solution of 10 mM magnesium sulfate for absorption at 37°C for 15 minutes. Thereto was added 10 ml of LB liquid medium containing 0.4 % maltose, 5 mM calcium chloride and ampicillin 50 µg/ml and the cells were further cultured at 37°C overnight. After bacteriolysis with addition of several drops of chloroform, the lysis solution was centrifuged to remove the intact E. coli cells and debris. To 5 ml of the obtained culture supernatant was added the same amount of an aqueous solution of 2.5 M sodium chloride containing 20 % polyethylene glycol 6,000 and the mixture was left to stand on ice for 1 hour. After centrifugation at 10,000 rpm, precipitated λgt11 phage was subjected to phenol treatment and isopropanol precipitation to recover phage DNA. About 150 µg of the obtained phage DNA was digested with EcoRI and then electrophoresed on 0.8 % agarose gel to separate DNA fragments derived from Haemophilus paragallinarum serotype A strain 221. Using Sephaglas™ BandPrep Kit (manufactured by Pharmacia), the DNA fragments were eluted and recovered from the gel in accordance with protocol attached thereto. All the DNA fragments obtained from ten positive phages had a length of about 1.2 kb. A DNA fragment (hereinafter referred to as "HPG1.2k DNA") obtained from the phage of a clone (clone 2) was used in the following test. (2) Nucleotide sequence of HPG1.2k DNA fragment Plasmid pUC119 (manufactured by Takara Shuzo K.K.) was digested with EcoRI and then treated with alkaline phosphatase to dephosphorize the 5' end. The cleaved pUC119 DNA was treated with phenol and chloroform and then harvested by precipitation with ethanol. The cleaved pUC119 and the HPG1.2k DNA fragment were ligated together with DNA Ligation Kit ver. 2 (manufactured by Takara Shuzo K.K.). Competent cells of E.coli strain JM109 (manufactured by Takara Shuzo K.K.) were transformed with the ligated product and then cultured on Circle Grow agar medium (manufactured by BIO101) containing 50 µg/ml of ampicillin at 37°C overnight. Colonies grown on the agar medium were inoculated to 0.5 ml of Circle Grow medium containing 50 µg/ml of ampicillin and cultured at 37°C for 5 hours. Plasmids were extracted from the cells by an alkali method and, after digestion with EcoRI, subjected to 0.8 % agarose gel electrophoresis to detect recombinant plasmids containing DNA fragment with the same length as the 1.2k DNA derived from Haemophilus paragallinarum serotype A strain 221, and thereby transformed E.coli were confirmed. The obtained transformants of E.coli were cultured on Circle Grow medium containing 50 µg/ml of ampicillin and then the recombinant plasmids (hereinafter referred to as "pUA1.2") were recovered from the cells by PEG precipitation method. Using a Primer Walking method, a nucleotide sequence of the HPG1.2k DNA fragment was analyzed using a DNA sequencer (Applied Biosytems 377). As a result, a sequence of 1170 nucleotides was determined. It was found that the nucleotide sequence of the HPG1.2k DNA corresponds to the sequence of from No. 1988 to No. 3157 in SEQ ID NO: 1, which is a nucleotide sequence coding for serotype A HMTp210 polypeptide as described hereinbelow, and codes for 389 amino acid residues with no initiation codon and termination codon within this region. A corresponding amino acid sequence was also shown which depicts no sequence equivalent to the N-terminal amino acid sequence of HPGp130 polypeptide. Accordingly, it was considered that HPG1.2k DNA codes for a portion of HPGp130 polypeptide. (3) Cloning of HPG3.5k DNA Using DIG-DNA Labeling Kit (manufactured by Boehringer Mannheim), about 0.3 µg of the above HPG1.2k DNA was labeled with digoxigenin (DIG) in accordance with protocol attached thereto. After the genomic DNA of Haemophilus paragallinarum serotype A strain 221 was cleaved with several restriction enzymes, a suitable amount of the cleaved products was electrophoresed on 0.8 % agarose gel and then transferred to Hybond N+ membrane (manufactured by Amersham). Using the DIG-labeled HPG1.2k DNA as a probe, a Southern hybridization was carried out with DIG Nucleic Acid Detection Kit (manufactured by Boehringer Mannheim) in accordance with protocol attached thereto for detection of desired DNAs. As a result, about 3.5 kb fragment obtained by HindIII digestion hybridized to the DIG-labeled HPG1.2k DNA. Thus, this fragment was separated on 0.8 % agarose gel electrophoresis and eluted and recovered from the gel with Sephaglas™ BandPrep Kit in accordance with protocol attached thereto. On the other hand, plasmid pUC119 was digested with HindIII and then treated with alkaline phosphatase to dephosphorize the 5' end. The cleaved pUC119 DNA was treated with phenol and chloroform and then recovered by precipitation with ethanol. The cleaved pUC119 and the above HindIII digest (about 3.5 kb) from the genome of Haemophilus paragallinarum serotype A strain 221 were ligated together with DNA Ligation Kit ver. 2. Competent cells of E.coli strain JM109 were transformed with the ligated product and then cultured on Circle Grow agar medium containing 50 µg/ml of ampicillin at 37°C overnight. To the agar medium where transformed E.coli grown was overlaid Hybond N+ membrane to lift the colonies. Using the DIG-labeled HPG1.2k DNA as a probe a colony hybridization was carried out in the conventional manner and positive clones were screened with DIG Nucleic Acid Detection Kit. The positive clones were cultured on Circle Grow medium containing 50 µg/ml of ampicillin. Plasmids were recovered from the cells by PEG precipitation method. The obtained recombinant plasmid (hereinafter referred to as "pUA3.5") was digested with HindIII and then electrophoresed on 0.8 % agarose gel to separate 3.5 kb DNA fragment derived from Haemophilus paragallinarum serotype A strain 221. Using Sephaglas™ BandPrep Kit, this DNA fragment (hereinafter referred to as "HPG3.5k DNA") was eluted and recovered in accordance with protocol attached thereto. E.coli UA3.5JM transformed with the recombinant plasmid has been deposited by the applicant as FERM BP-6083 at National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken) on September 5, 1996. (4) Expression of HPG3.5k DNA The expression vector pTrcHisC (manufactured by Invitrogen) was digested with HindIII and then treated with alkaline phosphatase to dephosphorize the 5' end. The cleaved pTrcHisC DNA was treated with phenol and chloroform and then recovered by precipitation with ethanol. The cleaved pTrcHisC and the above HPG3.5k DNA were ligated together with DNA Ligation Kit ver. 2. Competent cells of E.coli strain JM109 were transformed with the ligated product and then cultured on Circle Grow agar medium containing 50 µg/ml of ampicillin at 37°C overnight. Colonies grown on the agar medium were inoculated to 0.5 ml of Circle Grow medium containing 50 µg/ml of ampicillin and cultured at 37°C for 5 hours. Plasmids were extracted from the cells by an alkali method and, after digestion with HindIII, subjected to 0.8 % agarose gel electrophoresis to detect recombinant plasmids containing DNA fragment with the same length as the 3.5k DNA derived from Haemophilus paragallinarum serotype A strain 221, and thereby transformed E.coli cells were confirmed. The obtained transformants of E.coli were plated on 1 ml of Circle Grow medium containing 50 µg/ml of ampicillin and cultured at 37°C for 3 hours. Thereto was further added IPTG (final concentration of 1 mM) and the transformants were cultured at 37°C for additional 3 hours. The cells were harvested from the culture by centrifugation and suspended in 50 µl of PBS. The suspension of the cells (10 µl) was mixed with the same amount of 2 % SDS and the mixture was boiled for 5 minutes and 2 µl was then spotted on a nitrocellulose membrane. The nitrocellulose membrane was air-dried and then masked with PBS containing 5 % skim milk at 4°C overnight. Thereafter, the procedures as described in Example 2 (6) were repeated so that anti-HPGp130 polypeptide guinea pig serum, peroxidase-labeled anti-guinea pig IgG and a substrate were successively reacted. A series of these procedures gave E.coli which was transformed with a recombinant plasmid wherein HPG3.5k DNA was ligated in a right direction and expresses an antigen specifically reactive with anti-HPGp130 guinea pig serum. (5) Immunogenicity of HPG3.5k-HIS polypeptide The obtained transformants of E.coli were inoculated to 200 ml of Circle Grow medium containing 50 µg/ml of ampicillin and cultured at 37°C for 3 hours. Thereto was added IPTG (final concentration of 1 mM) and the transformants were cultured at 37°C for additional 3 hours. The cells were harvested from the culture by centrifugation and suspended in 10 ml of PBS. To the suspension was added lysozyme at 100 µg/ml for reaction at 4°C for 1 hour. The suspension was sonicated with Branson Sonifier 350 at 4°C for 10 minutes for bacteriolysis. Intact cells were removed by centrifugation and the obtained supernatant was used as a crude HPG3.5k-HIS polypeptide. Ten SPF white leghorn chickens of 8 weeks old were immunized by subcutaneously administering at the leg 0.5 ml of an emulsion prepared by thoroughly mixing the crude HPG3.5k-HIS polypeptide solution with the same amount of Freund's complete adjuvant. Three weeks later, the chickens were subcutaneously administered at the leg with 0.5 ml of an emulsion prepared similarly with Freund's incomplete adjuvant. Two weeks later, the chickens were boosted subcutaneously at the leg with an emulsion prepared similarly with Freund's incomplete adjuvant. Seven weeks after the first immunization, the chicken were challenged with Haemophilus paragallinarum serotype A strain 221. As a control, as described in Example 2 (7), one group was immunized with formalin-inactivated HPG serotype A strain 221 and another group was not immunized and both control groups were challenged similarly. The results are shown in Table 3. The group immunized with the crude HPG3.5k-HIS polypeptide showed protection against the onset of the disease in seven among ten chicken. The group immunized with the formalin-inactivated cells exhibited protection against the onset of the disease in all the chickens whereas the non-immunization group showed the symptoms in all the chickens. Immunization group Tested chicken Protected chicken Protection rate (%) Crude HPGp3.5k-HIS 10 7 70 Formalin-inactivated strain 221 10 10 100 Non immunization control 8 0 0 (6) Nucleotide sequence of HPG3.5k DNA fragment A nucleotide sequence of HPG3.5k DNA fragment was analyzed with a DNA sequencer as described above. As a result, a sequence of 3450 nucleotides was determined. The nucleotide sequence of HPG3.5k DNA fragment corresponds to the nucleotide sequence of from nucleotides No. 1 to No. 3450 in SEQ ID NO: 1. A region was found which codes for an amino acid sequence identical to that of the N-terminal of HPGp130 polypeptide. An open reading frame was obtained from HPG3.5k DNA in the same frame as that of HPGp130 polypeptide and it was found that translation starts at nucleotide No. 243 to code for 1069 amino acid residues. There was no termination codon within the region and thus it was assumed that HPG3.5k DNA codes for a portion of HPGp130 polypeptide. A corresponding amino acid sequence is also shown. (7) Cloning of HPG4.1k DNA The above HPG3.5k DNA fragment was labeled with DIG as described above. After the genomic DNA of Haemophilus paragallinarum serotype A strain 221 was cleaved with restriction enzymes XhoI and XbaI, a Southern hybridization was carried out as described in Example 3 (3) using the DIG-labeled HPG3.5k DNA or the DIG-labeled HPG1.2k DNA as a probe. As a result, DNAs of about 5.5 kb, about 4.1 kb and about 1 kb were detected with the DIG-labeled HPG3.5k DNA as a probe. When the DIG-labeled HPG1.2k DNA was used as a probe, DNAs of about 4.1 kb and about 1 kb were detected. Since there are two XhoI sites within the HPG3.5k DNA fragment as shown in Fig. 7, it was considered that the DNA of about 5.5 kb was a fragment corresponding to the 5' site from the first XhoI cleavage site, the DNA of about 4.1 kb was a fragment corresponding to the 3' site from the second XhoI cleavage site and the DNA of about 1 kb was a fragment between these two XhoI sites. Thus, the fragment of about 4.1 kb was separated and recovered on 0.8 % agarose gel electrophoresis. As shown in Fig. 8, plasmid pSP72 (manufactured by Promega) was digested with XhoI and XbaI and, after dephosphorizing the 5' end, ligated with the above XhoI-XbaI digest (about 4.1 kb) derived from the genome of Haemophilus paragallinarum serotype A strain 221. E.coli strain JM109 cells were transformed with the ligated product. For the obtained E.coli transformants, a colony hybridization was carried out using the DIG-labeled HPG3.5k DNA as a probe to screen positive clones. The positive clones were cultured on Circle Grow medium containing 50 µg/ml of ampicillin. Plasmids were recovered from the cells by PEG precipitation method. The obtained plasmid (hereinafter referred to as "pSA4.1"), in which the XhoI-XbaI digest fragment (hereinafter referred to as "HPG4.1k DNA") derived from Haemophilus paragallinarum serotype A strain 221 was incorporated, was digested with XhoI and XpnI and then electrophoresed on 0.8 % agarose gel to separate and recover a DNA fragment of about 4.1 kb, which was the above HPG4.1k DNA added with XbaI-KpnI fragment from the plasmid pSP72. (8) Expression of HPG4.1k DNA As described in Example 3 (4), the expression vector pTrcHisC was digested with XhoI and XpnI and, after dephosphorizing the 5' end, ligated with the above XhoI-XpnI digest of about 4.1 kb. E.coli strain JM109 cells were transformed with the ligated product. From the obtained transformants of E.coli , there was obtained E.coli which was transformed with a recombinant plasmid wherein HPG4.1k DNA was ligated in a right direction and expresses an antigen specifically reactive with anti-HPGp130 guinea pig serum. (9) Immunogenicity of HPG4.1k-HIS polypeptide The obtained transformants of E.coli were inoculated to 200 ml of Circle Grow medium containing 50 µg/ml of ampicillin and cultured at 37°C for 3 hours. Thereto was added IPTG (final concentration of 1 mM) and the transformants were cultured at 37°C for additional 3 hours. The cells were harvested from the culture by centrifugation and suspended in 10 ml of PBS. To the suspension was added lysozyme at 100 µg/ml for reaction at 4°C for 1 hour. The suspension was sonicated at 4°C for 10 minutes for bacteriolysis. Intact cells were removed by centrifugation and the obtained supernatant was used as a crude HPG4.1k-HIS polypeptide. Ten SPF white leghorn chickens of 5 weeks old were immunized by subcutaneously administering at the leg 0.5 ml of an emulsion prepared by thoroughly mixing the crude HPG4.1k-HIS polypeptide solution with the same amount of Freund's complete adjuvant. About three weeks later, the chickens were subcutaneously administered at the leg with 0.5 ml of an emulsion prepared similarly with Freund's incomplete adjuvant. Two weeks later, the chickens were boosted subcutaneously at the leg with an emulsion prepared similarly with Freund's incomplete adjuvant. Seven weeks after the first immunization, the chickens were challenged with Haemophilus paragallinarum serotype A strain 221. As a control, as described in Example 2 (7), one group was immunized with formalin-inactivated HPG serotype A strain 221 and another group was not immunized and both control groups were challenged similarly. The results are shown in Table 4. The group immunized with the crude HPG4.1k-HIS polypeptide showed protection against the onset of the disease in every ten among the tested chickens. The group immunized with the formalin-inactivated cells exhibited protection against the onset of the disease in all the chickens whereas the non-immunization group showed the symptoms in all the chickens. Immunization group Tested chicken Protected chicken Protection rate (%) Crude HPGp4.1k-HIS 10 10 100 Formalin-inactivated strain 221 10 10 100 Non immunization control 10 0 0 (10) Nucleotide sequence of HPG4.1k DNA fragment A nucleotide sequence of a region in HPG4.1k DNA fragment which does not overlap with HPG3.5k DNA fragment, i.e. a region ranging from the HindIII cleavage site to the XbaI cleavage site, was analyzed with a DNA sequencer as described above. As a result, a sequence of 2831 nucleotides was determined. The analyzed nucleotide sequence of HPG4.1k DNA fragment corresponds to the nucleotide sequence of from nucleotides No. 3445 to No. 6275 in SEQ ID NO: 1. No termination codon was found within the region of said DNA fragment. A corresponding amino acid sequence is also shown. (11) Cloning of HPG6.7k DNA After the genomic DNA of Haemophilus paragallinarum serotype A strain 221 was cleaved with XhoI and PstI, a Southern hybridization was carried out as described in Example 3 (3) using the DIG-labeled HPG3.5k DNA or the DIG-labeled HPG1.2k DNA as a probe. As a result, DNAs of about 9.4 kb, about 6.7 kb and about 1 kb were detected with the DIG-labeled HPG3.5k DNA as a probe. When the DIG-labeled HPG1.2k DNA was used as a probe, DNAs of about 6.7 kb and about 1 kb were detected. Since there are two XhoI cleavage sites within the HPG3.5k DNA fragment as described above, it was considered that the DNA of about 9.4 kb was a fragment corresponding to the 5' site from the first XhoI cleavage site, the DNA of about 6.7 kb was a fragment corresponding to the 3' site from the second XhoI cleavage site and the DNA of about 1 kb was a fragment between these two XhoI sites. Thus, the fragment of about 6.7 kb was separated and recovered on 0.8 % agarose gel electrophoresis. As shown in Fig. 9, plasmid pSP72 was digested with XhoI and PstI and, after dephosphorizing the 5' end, ligated with the above XhoI-PstI digest (about 6.7 kb) derived from the genome of Haemophilus Paragallinarum serotype A strain 221. E.coli strain JM109 cells were transformed with the ligated product. For the obtained E.coli transformants, a colony hybridization was carried out using the DIG-labeled HPG3.5k DNA as a probe to screen positive clones. The positive clones were cultured on Circle Grow medium containing 50 µg/ml of ampicillin. Plasmids were recovered from the cells by PEG precipitation method. The obtained recombinant plasmid is hereinafter referred to as "pSA6.7". E.coli SA6.7JM transformed with the recombinant plasmid has been deposited by the applicant as FERM BP-6081 at National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken) on August 27, 1997. (12) Cloning of HPG2.7k DNA Since the DNA fragment of about 6.7 kb (hereinafter referred to as "HPG6.7k DNA") incorporated in the obtained recombinant plasmid (pSA6.7) encompasses the above HPG4.1k DNA, a fragment of about 2.7 kb (hereinafter referred to as "HPG2.7k DNA") was subcloned which is a subtraction of HPG4.1k DNA from HPG6.7k DNA. pSA6.7 was digested with XbaI and then electrophoresed on 0.8 % agarose gel to separate and recover a DNA fragment of about 2.7 kb which was the above HPG2.7k DNA added with PstI-XbaI fragment from the plasmid pSP72. Plasmid pSP72 was then digested with XbaI and, after dephosphorizing the 5' end, ligated with the above XbaI digest of about 2.7 kb. E.coli strain JM109 cells were transformed with the ligated product. The obtained E.coli transformants were cultured on Circle Grow medium containing 50 µg/ml of ampicillin. Plasmids were recovered from the cells by PEG precipitation method. The obtained recombinant plasmid is hereinafter referred to as "pSA2.7". (13) Nucleotide sequence of HPG2.7k DNA A nucleotide sequence of HPG2.7k DNA fragment was analyzed with a DNA sequencer as described above. As a result, a sequence of 2661 nucleotides was determined. The nucleotide sequence of HPG2.7k DNA fragment corresponds to the nucleotide sequence of from nucleotides No. 6270 to No. 8930 in SEQ ID NO: 1. A termination codon was found within the region. A corresponding amino acid sequence is also shown. It was found that the nucleotide sequence of SEQ ID NO: I, consisting of a total of 8930 nucleotides, included an open reading frame starting from nucleotide No. 243 which can code for 2042 amino acid residues. A polypeptide comprising the 2042 amino acid residues is hereinafter referred to as serotype A HMTp210". Homology search with the existing data base (GeneBank and EMBL) revealed no homology with any known nucleotide and amino acid sequences, indicating that the serotype A HMTp210 polypeptide is a novel substance. The presence of another possible open reading frame in the nucleotide sequence of SEQ ID NO: 1 was also suggested which starts from nucleotide No. 8375 and can code for 185 amino acid residues. No termination codon was found in this sequence. Homology search with the existing data base (GeneBank and EMBL) revealed no homology with any known nucleotide and amino acid sequences, indicating that the polypeptide coded by this open reading frame is also a novel substance. Example 4 : Search for DNA fragment hybridizable to HPG1.2k DNA from other strains than Haemophilus paragallinarum serotype A strain 221 As described in Example 3 (1), genomic DNAs were prepared from a total of nine strains, i.e. HPG serotype A strains 221, 083, W, Germany and Georgia, HPG serotype B strains Spross and 0222, and HPG serotype C strains Modesto and 53-47. After the prepared genomic DNAs were cleaved with restriction enzyme EcoRI, a Southern hybridization was carried out using the DIG-labeled HPG1.2k DNA as a probe as described in Example 3 (3). As a result, fragments hybridizable with HPG1.2k DNA were detected in every strains although size of each fragment was varied depending on the strains (Fig. 10). Example 5 : Cloning of gene coding for polypeptide (serotype C HMTp210) from Haemophilus paragallinarum serotype C (1) Screening from genomic library A genomic library of Haemophilus paragallinarum serotype C strain 53-47 was prepared in the same manner as described in Example 3 (1). That is, a genomic DNA of HPG serotype C strain 53-47 digested with restriction enzyme HindIII was ligated to λDASHII (manufactured by STRATAGENE) arm digested with restriction enzyme HindIII using cDNA Rapid Cloning Module-λgt11. Using λ-DNA in vitro packaging module, the ligated product was inserted into λ phage. The obtained solutions of recombinant phage were used as a genomic library. The above solutions of genomic library were added to a suspension of E.coli strain XL1-Blue MRA (P2) (manufactured by STRATAGENE) about 10 8 cells in an aqueous solution of 10 mM magnesium sulfate for absorption at 37°C for 15 minutes. Thereto was added LB soft agarose medium (containing tryptone 10 g, yeast extract 5 g, sodium chloride 10 g, ampicillin 50 mg, maltose 4 g and agarose 8 g in 1000 ml, pH 7) for overlay warmed at 45°C. The mixture was overlaid to LB agar medium and incubated at 37°C overnight. To the agar medium where transformed E.coli grown was overlaid Hybond N+ membrane to lift the phage plaques. Using the DIG-labeled serotype A HPG3.5k DNA as a probe, a plaque hybridization was carried out in the conventional manner and positive clones were screened. About 1,000 plaques were immunologically screened as described above to give 37 positive plaques. Ten among the obtained positive plaques were further subjected to second and third screening as in the primary screening. The recombinant λDASHII phages found positive in the plaque hybridization were added to a suspension of E. coli strain XL1-Blue MRA (manufactured by STRATAGENE) about 10 8 cells in an aqueous solution of 10 mM magnesium sulfate for absorption at 37°C for 15 minutes. As described in Example 3 (1), the phage DNA was recovered. The obtained phage DNA was digested with HindIII and then electrophoresed on 0.8 % agarose gel to separate and recover DNA fragments derived from Haemophilus paragallinarum serotype C strain 53-47. All the DNA fragments obtained from ten positive phages had a length of about 13.5 kb. A DNA fragment (hereinafter referred to as "HPG-C1 DNA") obtained from the phage of a clone (clone 1) was used in the following test. (2) Fragmentation and subcloning of HPG-C1 DNA Since the HPG-C1 DNA of about 13.5 kb is too large to be subcloned into a plasmid vector, it was cleaved with several restriction enzymes and a suitable amount of the resulting DNA fragments was electrophoresed on 0.8 % agarose gel. As a result, DNA fragments of about 6.9 kb, about 5.6 kb and about 0.9 kb were detected when digested with XbaI. Plasmid pUC119 was digested with HindIII and XbaI and, after dephosphorizing the 5' end, ligated with the above XbaI digests of HPG-C1 DNA. E.coli strain JM109 cells were transformed with the ligated products. Furthermore, E.coli cells transformed with the recombinant plasmid containing either DNA fragment of about 5.6 kb or about 0.9 kb were cultured and the plasmids were recovered from the cells by PEG precipitation method. The obtained recombinant plasmids (hereinafter referred to as "pU-C2" and "pU-C3", containing either DNA fragment of about 5.6 kb and about 0.9 kb, respectively) was digested with HindIII-XbaI and then electrophoresed on 0.8 % agarose gel to separate and recover DNA fragments of about 5.6 kb and about 0.9 kb (hereinafter referred to as "HPG-C2 DNA" and "HPG-C3 DNA", respectively). E.coli U-C2JM transformed with the recombinant plasmid pU-C2 has been deposited by the applicant as FERM BP-6082 at National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken) on August 27, 1997. Plasmid pUC119 was digested with XbaI and, after dephosphorizing the 5' end, ligated with the above XbaI digests of HPG-C1 DNA. E.coli strain JM109 cells were transformed with the ligated products. Furthermore, E.coli cells transformed with the recombinant plasmid containing DNA fragment of about 6.9 kb were cultured and the plasmid was recovered from the cells by PEG precipitation method. The obtained recombinant plasmid (hereinafter referred to as "pU-C4") was digested with XbaI and then electrophoresed on 0.8 % agarose gel to separate and recover DNA fragment of about 6.9 kb (hereinafter referred to as "HPG-C4 DNA"). E.coli U-C4JM transformed with the recombinant plasmid pU-C4 has been deposited by the applicant as FERM BP-6080 at National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken) on August 27, 1997. Each of the obtained DNA fragments HPG-C2, HPG-C3 and HPG-C4 was spotted on Hybond N+ membrane. Then, a dot hybridization was carried out using as a probe either the above DIG-labeled HPG3.5k DNA or HPG4.1k or HPG2.7k DNA labeled similarly with DIG. When the DIG-labeled HPG3.5k DNA or DIG-labeled HPG4.1k DNA was used as a probe, HPG-C4 DNA was detected. On the other hand, when HPG2.7k DNA was used as a probe, HPG-C2 DNA was detected. From this, it was assumed that HPG-C3, HPG-C4 and HPG-C2 were positioned in this order from the 5' site and HPG-C4 mainly encompasses a region coding for the polypeptide as shown in Fig. 11. (3) Nucleotide sequence of HPG-C4 DNA fragment A nucleotide sequence of HPG-C4 DNA fragment was analyzed with a DNA sequencer as described above. As a result, a sequence of 6871 nucleotides was determined. The nucleotide sequence of HPG-C4 DNA fragment corresponds to the nucleotide sequence of from nucleotides No. 1 to No. 6871 in SEQ ID NO: 5. Based on high homology with the gene coding for serotype A HMTp210, an open reading frame was obtained from HPG-C4 DNA in the same frame as that of the gene coding for serotype A HMTp210 and it was found that translation starts at nucleotide No. 848 to code for 2008 amino acid residues. However, no termination codon was found within the region of said DNA fragment. A corresponding amino acid sequence was also shown. (4) Nucleotide sequence of a portion of HPG-C2 DNA fragment Since no termination codon was found within the region of HPG-C4 DNA fragment, a nucleotide sequence at the 5' site of HPG-C2 DNA fragment, which is at the 3' site of HPG-C4 DNA fragment, was analyzed. As shown in Fig. 11, there are three AccI cleavage sites within HPG-C2 DNA fragment. It was also revealed that a fragment ranging from the cloning site, i.e. XbaI cleavage site, to the first AccI cleavage site is of size about 0.6 Kb as demonstrated in an agarose gel electrophoresis. Thus, a nucleotide sequence of this fragment of about 0.6 Kb was analyzed with a DNA sequencer as described above. As a result, a sequence of 621 nucleotides was determined. The nucleotide sequence of a portion of HPG-C2 DNA fragment corresponds to the nucleotide sequence of from nucleotides No. 6866 to No. 7486 in SEQ ID NO: 5. A termination codon was found within the region of this portion of HPG-C2 DNA fragment. A corresponding amino acid sequence was also shown. It was found that the nucleotide sequence of SEQ ID NO: 5, consisting of a total of 7486 nucleotides, included an open reading frame starting from nucleotide No. 848 which can code for 2039 amino acid residues. A polypeptide comprising the 2039 amino acid residues is hereinafter referred to as "serotype C HMTp210". Homology search with the existing data base (GeneBank and EMBL) revealed no homology with any known nucleotide and amino acid sequences, indicating that the serotype C HMTp210 polypeptide is a novel substance. Homology search between the nucleotide sequences coding for the serotype C HMTp210 polypeptide and the serotype A HMTp210 polypeptide revealed about 80 % homology. It was further revealed that the region of about 3.4 kb at the 5' site and the region of about 1.2 kb at the 3' site exhibited extremely high homology whereas the region of about 1.5 kb between these 5' and 3' regions showed low homology. The same was also applicable to the corresponding polypeptides encoded by these genes. Example 6 : PCR amplification of HMTp210 gene from genomic DNA of HPG serotypes A, B and C cells As described in Example 3 (1), genomic DNAs were prepared from a total of nine strains, i.e. HPG serotype A strains 221, 083, W, Germany and Georgia, HPG serotype B strains Spross and 0222, and HPG serotype C strains Modesto and 53-47. Based on the nucleotide sequence coding for the Type A HMTp210 polypeptide, there were prepared a synthetic DNA having the nucleotide sequence of SEQ ID NO: 3 as an upstream PCR primer and a synthetic DNA having the nucleotide sequence of SEQ ID NO: 4 as a downstream PCR primer. These primers were designed such that BamHI recognition sequences were added at the 5' site, respectively, and a full length of translation region of the serotype A HMTp210 polypeptide can be amplified. Using these primers, PCR was carried out using the genomic DNAs prepared as mentioned above as a template. PCR was carried out with LA PCR Kit ver. 2 (manufactured by Takara Shuzo K.K.) under the following conditions: after reaction at 94°C for 1 minute, 30 cycles of reactions at 98°C for 40 seconds and at 60°C for 10 minutes, followed by reaction at 72°C for 10 minutes. Analysis of the obtained PCR products on 0.8 % agarose gel electrophoresis confirmed the amplified fragment of about 6.1 Kb in any of these strains (Fig. 12). Example 7 : Expression of full-length serotypes A and C HMTp210 polypeptides (1) Expression of serotype A HMTp210 polypeptide The PCR product obtained in Example 6 with the genomic DNA from Haemophilus paragallinarum serotype A strain 221 as a template was digested with BamHI. After separation on 0.8 % agarose gel electrophoresis, the amplified fraction of about 6.1 Kb was eluted and recovered with Sephaglas™ BandPrep Kit. Plasmid pUC119 was digested with BamHI and, after dephosphorizing the 5' end, ligated with the above amplified fragment of about 6.1 kb. E.coli strain JM109 cells were transformed with the ligated product. Furthermore, E.coli cells transformed with the recombinant plasmid containing DNA fragment of about 6.1 kb were cultured and the plasmid was recovered from the cells by PEG precipitation method. The obtained recombinant plasmid (hereinafter referred to as "pU-AP1") was digested with BamHI and then electrophoresed on 0.8 % agarose gel to separate and recover DNA fragment of about 6.1 kb (hereinafter referred to as "HPG-AP1 DNA"). As described in Example 3 (4), the expression vector pTrcHisA (manufactured by Invitrogen) was digested with BamHI and, after dephosphorizing the 5' end, ligated with the above HPG-AP1 DNA. E.coli strain JM109 cells were transformed with the ligated product. From the obtained transformants of E.coli , there was obtained E.coli which was transformed with a recombinant plasmid wherein HPG-AP1 DNA was ligated in a right direction and expressed an antigen specifically reactive with anti-HPGp130 guinea pig serum. (2) Expression of serotype C HMTp210 polypeptide The PCR product obtained in Example 6 with the genomic DNA from Haemophilus paragallinarum serotype C strain 53-47 as a template was digested with BamHI. After separation on 0.8 % agarose gel electrophoresis, the amplified fraction of about 6.1 kb was recovered. Plasmid pUC119 was digested with BamHI and, after dephosphorizing the 5' end, ligated with the above amplified fragment of about 6.1 kb. E.coli strain JM109 cells were transformed with the ligated product. Furthermore, E.coli cells transformed with the recombinant plasmid containing DNA fragment of about 6.1 kb were cultured and the plasmid was recovered from the cells by PEG precipitation method. The obtained recombinant plasmid (hereinafter referred to as "pU-CP1") was digested with BamHI and then electrophoresed on 0.8 % agarose gel to separate and recover DNA fragment of about 6.1 kb (hereinafter referred to as "HPG-CP1 DNA"). As described in Example 3 (4), the expression vector pTrcHisA (manufactured by Invitrogen) was digested with BamHI and, after dephosphorizing the 5' end, ligated with the above HPG-CP1 DNA. E.coli strain JM109 cells were transformed with the ligated product. From the obtained transformants of E.coli , there was obtained E.coli which was transformed with a recombinant plasmid wherein HPG-CP1 DNA was ligated in a right direction and expressed an antigen specifically reactive with anti-HPGp130 guinea pig serum. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute (B) STREET: 6-1, Okubo 1-chome (C) CITY: Kumamoto-ken (D) STATE: Kumamoto-shi (E) COUNTRY: Japan (F) POSTAL CODE (ZIP): 860 (ii) TITLE OF INVENTION: NOVEL POLYPEPTIDE FROM HAEHOPHILUS PARAGALLINARUM AND PROCESS FOR PREPARING THE SAME (iii) NUMBER OF SEQUENCES: 5 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO) (v) CURRENT APPLICATION DATA: APPLICATION NUMBER: EP 97 94 0361.5 SEQ ID NO.: 1 SEQUENCE LENGTH: 8930 SEQUENCE TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear MOLECULE TYPE: genomic DNA ORIGINAL SOURCE: Haemophilus paragallinarum serotype A strain 221 SEQUENCE DESCRIPTION: SEQ ID NO.: 2 SEQUENCE LENGTH: 13 SEQUENCE TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: peptide ORIGINAL SOURCE: Haemophilus paragallinarum serotype A strain 221 SEQUENCE DESCRIPTION: SEQ ID NO: 3 SEQUENCE LENGTH: 43 SEQUENCE TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: other nucleic acid (synthetic DNA) SEQUENCE DESCRIPTION: SEQ ID NO.: 4 SEQUENCE LENGTH: 39 SEQUENCE TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: other nucleic acid (synthetic DNA) SEQUENCE DESCRIPTION: SEQ ID NO. : 5 SEQUENCE LENGTH: 7486 SEQUENCE TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear MOLECULE TYPE: genomic DNA ORIGINAL SOURCE: Haemophilus paragallinarum serotype C strain 53-47 SEQUENCE DESCRIPTION:

Claims: A recombinant polypeptide from Haeamophilus paragallinarum capable of inducing production of HI antibody and/or protecting against avian infectious coryza selected from the group consisting of (a) polypeptides having the amino acid sequence as shown in SEQ ID NO: 1 or in SEQ ID NO:5; (b) polypeptides having the amino acid sequence at the N-terminal end as shown in SEQ NO: 2 and having a molecular weight of about 130 kD; (c) polypeptides having the amino acid sequence encoded by the nucleotide sequence of from nucleotide residues NO: 2212 to NO: 6275 of SEQ ID NO: 1; and (d) polypeptides having the amino acid sequence encoded by the nucleotide residues NO:1 to NO: 3450 of SECT ID NO: 1. The polypeptide of claim 1 wherein Haemophilus paragallinarum is Haemophilus paragallinarum serotype A or serotype C. The polypeptide of claim 1 or 2, wherein one or several amino acid residues are deleted, added or substituted. A DNA having a nucleotide sequence coding for the polypeptide of any one of claims 1 to 3. The DNA of claim 4 which comprises the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 5. A DNA coding for a polypeptide from Haemophilus paragallinarum capable of inducing production of HI antibody and/or protecting against avian infectious coryza which hybridizes with a DNA of a nucleotide sequence complementary to the nucleotide sequence as shown in SEQ ID NO: 1 or SEPA ID NO: 5. A recombinant DNA molecule comprising the DNA of any one of claims 4 to 6. The recombinant DNA molecule of claim 7 wherein a vector of said recombinant DNA molecule is selected from the group consisting of a plasmid, a viral vector and a cosmid. A transformant cell transformed with either the DNA of any one of claims 4 to 6 or the recombinant DNA molecule as set forth in claim 7 or 8. The transformant cell of claim 9 which is a host selected from the group consisting of bacteria, yeast, insect cell, animal cell and plant cell. An antibody which recognizes the polypeptide of any one of claims 1 to 3. The antibody of claim 11 which is a monoclonal antibody or a polyclonal antibody. A process for preparing the polypeptide as set forth in claim 1 or 3 by using monoclonal antibody having HI activity. The process of claim 13 wherein said polypeptide is derived from Haemophilus paragallinarum. The process of claim 14 wherein Haemophilus paragallinarum is Haemophilus paragallinarum serotype A or serotype C. A process for preparing the polypeptide of any one of claims 1 to 3 which comprises culturing the transformant cell as set forth in claim 9 or 10 so that said transformant cell could produce the polypeptide of any one of claims 1 to 3, and purifying said polypeptide: An immunogenic composition comprising the polypeptide of any one of claims 1 to 3, the DNA of any one of claims 4 to 6, the recombinant DNA molecule as set forth in claim 7 or 8 or the transformant cell as set forth in claim 9 or 10 and, optionally, a suitable carrier, diluent or stabilizing agent. The immunogenic composition according to claim 17 for protection against avian infectious coryza. A therapeutic agent comprising as an active ingredient the antibody as set forth in claim 11 or 12, the polypeptide of any one of claims 1 to 3 or the vector of claim 8 and, optionally, a suitable carrier, diluent or stabilizing agent. A therapeutic agent according to claim 19 for avian infectious coryza. A vaccine composition comprising a recombinant polypeptide from Haemophilus paragallinarum capable of inducing production of HI antibody and/or protecting against avian infectious coryza selected from the group consisting of: (a) polypeptides having the amino acid sequence at the N-terminal end as shown in SEQ NO: 2 and having a molecular weight of about 130 kD; (b) polypeptides having the amino acid sequence encoded by the nucleotide sequence of from nucleotide residues NO: 2212 to NO: 6275 of SEQ ID NO: 1; and (c) polypeptides having the amino acid sequence encoded by the nucleotide residues NO:1 to NO: 3450 of SEQ ID NO: 1. The vaccine according to claim 21 for protection against avian infectious coryza

Inventors: HAMADA FUKUSABURO, MATSUO KAZUO, SAKAGUCHI MASASHI, TOKIYOSHI SACHIO, TOKUNAGA EIJI, HAMADA, FUKUSABURO, MATSUO, KAZUO, SAKAGUCHI, MASASHI, TOKIYOSHI, SACHIO, TOKUNAGA, EIJI, HAMADA, Fukusaburo 2679-2, Suya
Applicants: CHEMO SERO THERAPEUT RES INST, JURIDICAL FOUNDATION, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Application year: 1997
Main classification: C12N15
IPC codes: A61K38, C07K7, A61K39, C07K14, G01N33, A61P31, C12N15, C12N1, C12P21, C12R1